Free Trial

Athersys (ATHX) Competitors

Athersys logo

ATHX vs. GLTO, KZIA, HEPA, SPRC, ARAV, ENVB, RDHL, SNPX, REVB, and MTNB

Should you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Galecto (GLTO), Kazia Therapeutics (KZIA), Hepion Pharmaceuticals (HEPA), SciSparc (SPRC), Aravive (ARAV), Enveric Biosciences (ENVB), RedHill Biopharma (RDHL), Synaptogenix (SNPX), Revelation Biosciences (REVB), and Matinas Biopharma (MTNB). These companies are all part of the "pharmaceutical preparations" industry.

Athersys vs.

Galecto (NASDAQ:GLTO) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.

Athersys received 333 more outperform votes than Galecto when rated by MarketBeat users. However, 60.38% of users gave Galecto an outperform vote while only 56.33% of users gave Athersys an outperform vote.

CompanyUnderperformOutperform
GalectoOutperform Votes
32
60.38%
Underperform Votes
21
39.62%
AthersysOutperform Votes
365
56.33%
Underperform Votes
283
43.67%

Galecto presently has a consensus target price of $10.00, suggesting a potential upside of 257.14%. Given Galecto's stronger consensus rating and higher probable upside, research analysts plainly believe Galecto is more favorable than Athersys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galecto
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Athersys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Athersys' return on equity of 0.00% beat Galecto's return on equity.

Company Net Margins Return on Equity Return on Assets
GalectoN/A -76.96% -66.59%
Athersys N/A N/A -223.03%

In the previous week, Galecto and Galecto both had 1 articles in the media. Galecto's average media sentiment score of 1.87 beat Athersys' score of 0.00 indicating that Galecto is being referred to more favorably in the media.

Company Overall Sentiment
Galecto Very Positive
Athersys Neutral

Galecto has higher earnings, but lower revenue than Athersys. Galecto is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GalectoN/AN/A-$38.35M-$18.61-0.15
Athersys$146K0.00-$72.53M-$2.03N/A

Galecto has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500.

14.2% of Galecto shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 11.9% of Galecto shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Galecto beats Athersys on 9 of the 15 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHX vs. The Competition

MetricAthersysPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$833,000.00$6.89B$5.56B$7.82B
Dividend YieldN/A3.05%5.11%4.22%
P/E Ratio0.007.4422.5118.48
Price / SalesN/A242.70395.68103.60
Price / CashN/A65.8538.1834.62
Price / BookN/A6.516.774.25
Net Income-$72.53M$143.21M$3.22B$248.23M

Athersys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHX
Athersys
N/AN/AN/AN/A$833,000.00$146,000.000.0024Analyst Forecast
News Coverage
GLTO
Galecto
3.1118 of 5 stars
$2.42
-0.4%
$10.00
+313.2%
-83.7%$3.20MN/A-0.1340Upcoming Earnings
Positive News
KZIA
Kazia Therapeutics
3.7785 of 5 stars
$3.09
-6.4%
$11.50
+272.2%
-78.6%$3.11M$2.31M0.0012Positive News
HEPA
Hepion Pharmaceuticals
0.2703 of 5 stars
$0.27
-16.2%
N/A-99.6%$2.96MN/A-0.0620News Coverage
Gap Down
SPRC
SciSparc
0.965 of 5 stars
$0.27
-3.4%
N/A-80.5%$2.96M$1.75M0.004Short Interest ↓
Positive News
ARAV
Aravive
N/A$0.04
flat
N/AN/A$2.95M$6.99M0.0020High Trading Volume
ENVB
Enveric Biosciences
2.6494 of 5 stars
$1.19
+1.7%
$10.00
+740.3%
-90.6%$2.94MN/A-0.0320Positive News
RDHL
RedHill Biopharma
1.0685 of 5 stars
$2.17
-4.0%
N/A-99.2%$2.89M$8.04M0.00210Analyst Forecast
Gap Down
SNPX
Synaptogenix
2.7766 of 5 stars
$2.05
-3.3%
$14.00
+582.9%
-48.7%$2.85MN/A-0.194Positive News
Gap Down
REVB
Revelation Biosciences
0.4587 of 5 stars
$3.14
+1.9%
N/A-91.0%$2.84MN/A-0.0110Short Interest ↑
Negative News
Gap Up
MTNB
Matinas Biopharma
N/A$0.56
-7.2%
N/A+218.3%$2.83M$1.10M-0.1130

Related Companies and Tools


This page (NASDAQ:ATHX) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners